OPKO Health Inc
NASDAQ:OPK
Intrinsic Value
OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. [ Read More ]
The intrinsic value of one OPK stock under the Base Case scenario is 1.91 USD. Compared to the current market price of 1.23 USD, OPKO Health Inc is Undervalued by 36%.
Valuation Backtest
OPKO Health Inc
Run backtest to discover the historical profit from buying and selling OPK stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
OPKO Health Inc
Current Assets | 309.5m |
Cash & Short-Term Investments | 95.9m |
Receivables | 130.2m |
Other Current Assets | 83.4m |
Non-Current Assets | 1.7B |
Long-Term Investments | 16.1m |
PP&E | 143.5m |
Intangibles | 1.5B |
Other Non-Current Assets | 9.1m |
Current Liabilities | 200.1m |
Accounts Payable | 69.7m |
Accrued Liabilities | 98.9m |
Other Current Liabilities | 31.5m |
Non-Current Liabilities | 422.4m |
Long-Term Debt | 229.3m |
Other Non-Current Liabilities | 193.1m |
Earnings Waterfall
OPKO Health Inc
Revenue
|
863.5m
USD
|
Cost of Revenue
|
-545.4m
USD
|
Gross Profit
|
318.1m
USD
|
Operating Expenses
|
-475.1m
USD
|
Operating Income
|
-157m
USD
|
Other Expenses
|
-31.8m
USD
|
Net Income
|
-188.9m
USD
|
Free Cash Flow Analysis
OPKO Health Inc
OPK Profitability Score
Profitability Due Diligence
OPKO Health Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
OPKO Health Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
OPK Solvency Score
Solvency Due Diligence
OPKO Health Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Score
OPKO Health Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
OPK Price Targets Summary
OPKO Health Inc
According to Wall Street analysts, the average 1-year price target for OPK is 4.34 USD with a low forecast of 1.52 USD and a high forecast of 8.93 USD.
Ownership
OPK Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
OPK Price
OPKO Health Inc
Average Annual Return | 21.79% |
Standard Deviation of Annual Returns | 113.29% |
Max Drawdown | -86% |
Market Capitalization | 857.3m USD |
Shares Outstanding | 696 990 000 |
Percentage of Shares Shorted | 25.26% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. The company is headquartered in Miami, Florida and currently employs 5,767 full-time employees. The Company’s segments include Diagnostics and Pharmaceutical. The Diagnostics segment consists of the clinical laboratory operations of Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women's Health) and GeneDx. Its Pharmaceutical Business have one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Oxyntomodulin, Biologics, Factor VIIa -CTP and hGH-CTP. The company also owns an active pharmaceutical ingredients (APIs) manufacturer in Israel through its subsidiary FineTech Pharmaceutical, Ltd.
Contact
IPO
Employees
Officers
The intrinsic value of one OPK stock under the Base Case scenario is 1.91 USD.
Compared to the current market price of 1.23 USD, OPKO Health Inc is Undervalued by 36%.